

Prevalence of Abnormal Ankle –Brachial Index in Iraqi Patients with Systemic Lupus Erythematosus

Ziad S. Al-Rawi* , Faiq I. Gorial* , Abdullateef Aliasghar Mustafa*** ,
Kais Hasan Abd****, Wessen A. Hassoon**

ABSTRACT:

BACKGROUND:

Accelerated atherosclerosis is a well-recognized complication of systemic lupus erythematosus (SLE). Its etiology is a multifactorial and several methods may be used to detect the presence and severity of peripheral arterial disease (PAD).

OBJECTIVE:

To assess ankle brachial index (ABI) in Iraqi patients with SLE, and to evaluate predictors of this relationship.

PATIENTS AND METHODS:

Forty three Iraqi SLE patients and 50 healthy controls were included in this study. Full history was taken and complete clinical examination was done for all individuals in both groups. Disease characteristics [age, sex, body mass index (BMI), duration of disease, SLE disease activity index (SLEDAI), smoking history, family history, hypertension, hyperlipidemia, thrombosis, Raynaud's phenomenon and drugs used] were also documented. Laboratory analysis included complete blood count, general urine examination, serum lipid profile, fasting blood sugar, thyroid function tests, anti-double stranded deoxyribonucleic acid (anti-ds-DNA), complements components and anti-phospholipid anti-bodies. Individuals in both groups were assessed using the ABI. The ABI was measured using a contour wrapped 12cm cuff attached to a mercury sphygmomanometer and 5-10 MHz Doppler in the arms and legs; a ratio of ≤ 0.9 was considered abnormal. Abnormal ABI was categorized as mild, moderate and severe.

RESULTS:

Seven (16%) Iraqi SLE patients have abnormal ABI compared with 0% of controls ($P=0.010$). All patients were of mild abnormal ABI ($P=0.003$). There was significant association between abnormal ABI and: sex, smoking history, and cyclophosphamide therapy ($P=0.000$, $P=0.001$, $P=0.020$ respectively) but there was no significant association between abnormal ABI; and other patients' characteristics [age, BMI, duration of disease, SLEDAI, family history, hypertension, thrombosis, Raynaud's phenomenon, or drugs used (steroid, mycophenolate mofetil, hydroxychloroquin, non-steroidal anti-inflammatory drugs and statins)] ($P=0.579$, $P=0.754$, $P=0.823$, $P=0.148$, $P=0.655$, $P=0.233$, $P=0.655$, $P=0.241$, $P=0.512$, $P=0.335$, $P=0.315$, $P=0.655$, $P=0.185$) respectively.

CONCLUSION:

Mild abnormal ABI occurs with high frequency (16%) in Iraqi SLE patients. Males, smoking history, and cyclophosphamide therapy are significant predictors.

KEY WORDS: Anke brachial index (ABI), systemic lupus erythematosus (SLE), abnormal ABI in SLE

INTRODUCTION:

Systemic lupus erythematosus (SLE) is a relapsing-remitting autoimmune disease with wide ranging organ involvement and clinical symptoms varying

from mild and transient symptoms to death.⁽¹⁾

Accelerated atherosclerosis is now recognized as a significant cause of morbidity and mortality in SLE, Urowitz et al⁽²⁾ were the first to observe this, and the diagnosis of SLE remains one of many risk factors of atherosclerosis⁽³⁾, so identifying subclinical atherosclerosis or vascular changes is gaining considerable attention.

Ankle brachial index (ABI) is an as an easy, reliable and non-invasive measure of the presence and severity of peripheral arterial disease (PAD)⁽⁴⁾. Measurement of ABI allows the identification of

*Baghdad University, College of Medicine, Medical Department, Rheumatology Unit.

**Baghdad Teaching Hospital, Medical Department, Rheumatology Unit.

***Institute of Radiology.

**** Surgical Hospital, Medical Department, Nephrology Unit.

both symptomatic and asymptomatic patients with PAD. Therefore, ABI is widely recommended for PAD screening⁽⁵⁾.

Recently published guidelines by the American Heart Association and the American College of Cardiology⁽⁶⁾ have suggested that the ABI should be considered for the purposes of cardiovascular risk assessment.

The aim of the study was to assess the prevalence of abnormal ABI in 43 Iraqi SLE patients and compared to 50 healthy controls.

PATIENTS AND METHODS:

PATIENTS

A cross-sectional study was conducted on 43 Iraqi patients with SLE who were seen at the Rheumatology Unit, Department of Medicine in Baghdad Teaching Hospital and Kidney Transplantation Centre in Surgical Specialized Hospital from January 2010 to July 2010.

The diagnosis of SLE was made using the criteria developed by the American College of Rheumatology^(7,8). For comparative purposes, 50 healthy control individuals were selected from healthy individuals that did not have symptoms of SLE and were not taking any medications.

All patients were screened clinically for conventional atherosclerotic risk factors (weight, height, smoking status, and family history of ischemic heart diseases) and by notes review (diabetes, nephrotic syndrome, history of thrombosis, presence of Raynaud’s phenomenon, current or past steroid treatment), disease duration, activity index using (SLEDAI: SLE disease activity index)⁽⁹⁾ and drugs used in the management of SLE patients. Patients were excluded from the study if they had other causes that might be implied in atherosclerosis like diabetes mellitus, hypothyroidism, nephrotic syndrome, rheumatoid arthritis and other connective tissue diseases.

METHODS:

Ankle brachial index (ABI) was calculated using the following formula⁽¹⁰⁻¹²⁾

$$ABI =$$

Highest each ankle pressure

Highest brachial pressure

Then we use the lowest ABI value of the left and right limbs to stratify patient’s risk. Interpretation of ABI¹³⁻¹⁵: Normal ABI: $\geq 0.91 - \leq 1.30$; An ABI ≤ 0.90 is diagnostic of PAD (mild PAD: 0.70- 0.90 , moderate PAD: 0.41-0.69, severe PAD or Critical Limb Ischemia: ≤ 0.4 , Non-compressible: ≥ 1.3). Blood sample was obtained

for measurement of haemoglobin, white blood cells, platelets, serum lipid profile, fasting blood sugar , and lupus serology anti-double stranded-DNA (anti-ds-DNA), complements components and antiphospholipid antibodies. Urine examination was done for measurement of protein, white blood cells, red blood cells and cellular casts. A signed consent was taken from the individuals in both groups for admission in the study. Ethical approval was obtained from the Ethics Committee of Baghdad University, College of Medicine, Medical Department.

Statistical analysis:

statistical analysis was done using analysis package for social science version 17 (SPSS V17). Association between discrete variables was measured by Chi square test and Fisher Exact test where appropriate. Difference between continuous variables was measured by t-test. Findings with P-values < 0.05 considered significant.

RESULTS:

Forty three patients with SLE, 39 females (90.7%) and 4 males (9.3%), their mean age (30.9+-11.1) years, and 50 control group, 45 females (90%) and 5(10%), their mean age (33.1+-11.2) years were included in this study .The age and sex of patients and control groups are shown in Table 1 (P-value=0.358 and 0.881 respectively) indicating no statistical difference between both groups.

Ankle-brachial index (ABI) was abnormal in 7(16%) patients, and normal in 36(84%), patients while it was normal in all 50(100%) healthy individuals of control group (p-value=0.010) which is statistically highly significant as shown in Table 2.

The abnormal ABI was mild in all 7 patients (P-value=0.003) which is statistically highly significant as shown in Table 3.

We found that there is highly statistical significant association between abnormal ABI and: male sex, and smoking history of patients (P-value=0.00 and P-value=0.001 respectively) and statistical significant association with cyclophosphamide therapy (P-value=0.020) as shown in Table 4.

We found that there is no statistical significant association between abnormal ABI and other SLE patients characteristics (age, BMI, duration of disease, disease activity index (SLEDAI), family history hypertension, hyperlipidemia, thrombosis, Raynaud’s phenomenon and other medication), as shown in Table 4.

Table 1: Demographic characteristics of 43 SLE patients and 50 controls

Variables	Patients = 43	Controls = 50	p-value
Age (years) Mean ± SD	30.9 ± 11.1	33.1 ± 11.2	0.358 ^{ns}
Sex			
Male n. (%)	4 (9.3)	5 (10)	0.881 ^{ns}
Female n. (%)	39 (90.7)	45 (90)	

ns, not significant; SD, standard deviation; n, number; %, percent

Table 2: Comparison of Ankle Brachial Index (ABI) in 43 patients and 50 controls.

Study group	ABI		p-value
	Abnormal (≤ 0.9) n. (%)	Normal (> 0.9) n. (%)	
Patients =43	7(16.0)	36(84)	0.010 *
Controls = 50	0(0.0)	50(100.0)	

*, P- value is significant; n, number; %, percent.

Table 3: Distribution of ABI severity in 43 SLE patients and 50 controls.

Severity	Patients n=43(100.0%)	Controls n=50(100.0%)	P-value
Normal ABI (>0.9)	36(84.0)	50(100.0)	
Mild (0.7_0.9)	7(16.0)	0(0.0)	0.003 **
Moderate (0.4_0.6)	0(0.0)	0(0.0)	
Severe (<0.4)	0(0.0)	0(0.0)	

**, highly significant; n, number; %, percent

**Table 4: Association between abnormal ABI in 43 SLE patients and patients` characteristics
ABI, ankle brachial index.**

Variables	ABI		P-value
	Abnormal N=7 (100.0%)	Normal N=36 (100.0%)	
Age (year); Mean ± SD	33.0 ± 8.2	30.4 ± 11.7	0.579
Sex; n(%)			0.000**
Male	3(75.0)	1(25.0)	
Female	4(11.4)	35(88.6)	
BMI(kg/m ²); Mean ± SD	24.3 ± 3.5	23.8 ± 3.8	0.754
Duration of disease (year); Mean ± SD	5.9 ± 2.34	6.4 ± 6.5	0.823
Activity of disease; n (%)			0.148
Active	5(25.0)	15(75.0)	
Inactive	2(8.7)	21(91.3)	
Smoking; n(%)			0.001 **
Current	0(0.0)	0(0.0)	
Ex smoker	2(28.6)	0(0.0)	
Never	5(71.4)	36(100.0)	
Family history; n (%)	0 (0.0)	1(100.0)	0.655
Hypertension; n (%)	4(25.0)	12(75.0)	0.233
Hyperlipidemia; n (%)	0 (0.0)	0 (0.0)	***
Thrombosis; n (%)	0 (0.0)	1(100.0)	0.655
Raynaud's Phenomenon; n(%)	2(28.5)	19(52.7)	0.241
Medication; n (%)			0.512
Steroid	5(13.2)	33(86.8)	
Mycophenolate mofetil	2(28.6)	5(71.4)	
Cycophosphamide	4(40.0)	6(60.0)	
Hydroxychloroquin	1(7.7)	12(92.3)	
NSAIDS	0(0.0)	1(100.0)	
Statins	1(50.0)	1(50.0)	

** , P- value is highly significant, * P- value is significant ; n, number, %,percent ,

DISCUSSION:

In the present study we observed a significant association between abnormal ABI and SLE patients. Possible explanation is that in SLE there is vascular inflammation which is mediated by immune complexes that may result in atheroma⁽¹²⁾. Up to the best of our knowledge this is the 1st cross sectional study investigating ABI in Iraqi SLE patients. Mortality due to coronary artery disease accounts for up to 30% of all deaths in patients with SLE⁽¹³⁾. There has been a dramatic change in the approach to studying cardiovascular disease. The ABI measurement can be conducted at low cost, using simple techniques and is non-invasive and it is an

easy, quick, and accurate. Furthermore, only minimal training is required to use the technique. It can be used as a primary prevention tool in routine screening of cardiovascular status in the community⁽¹⁴⁻¹⁸⁾ and has high patient acceptability. In attempting to prevent initial cardiovascular events in SLE patients, a reasonable strategy would be to target and treat patients with asymptomatic subclinical atherosclerosis and controlling its risk factor using anti-platelet drugs and encouraging lifestyle changes such as stopping smoking, diet, exercise and controlling of disease activity¹². In the present study, abnormal ABI was observed in 7(16%) SLE patients compared to 0 (0%)

control, (P-value =0.010) which may indicate a significant association between abnormal ABI and SLE patients. This agreed with other studies done by Theodoridou A et al ¹², and Lijmer JG et al ⁽¹⁹⁾. The prevalence of abnormal ABI in SLE was less in comparison to its prevalence in rheumatoid arthritis (25%) ⁽²⁰⁾, in antiphospholipid syndrome (23%) ⁽²¹⁾, and in primary Sjogren's syndrome (20%) ⁽²²⁾.

Mildly abnormal (0.7-0.9) ABI form is the only detected form among our SLE patients compared to controls (P=0.003) which may indicate a highly statistical significant difference between patients and controls. There were no other reports to compare with.

Male sex showed significant association with abnormal ABI in SLE patients which contrasted with another study done by Theodoidou A et al ⁽¹²⁾. This might be explained because most of the males have abnormal ABI in our study although their number is small[(3(75%) abnormal ABI versus 1(25%)normal ABI in comparison to females although their total number was more[4(11.4%) abnormal ABI versus 35(88.6) normal ABI].

Smoking history showed significant association with abnormal ABI in SLE patients which is in agreement with by Theodoidou A et al ⁽¹²⁾.

Other SLE patients characteristics (age, BMI ,duration of disease, family history, hypertension, hyperlipidemia , thrombosis ,Raynaud's phenomenon and medications (except cyclophosphamide) are not significantly associated with abnormal ABI .This agreed with other studies done by Newman AB et al ⁽¹⁶⁾, Satish et al ⁽²²⁾, and Khudhir ZM ⁽²³⁾. Possible explanation is that immune-inflammatory disease influences early atherosclerosis independently of the traditional risk factors, and for cyclophosphamide the result might be related to the severity of the disease and renal involvement.

A number of limitations of the current study must be pointed out. The small number of patients and being a cross-sectional study might limit the cause and effect relationship between abnormal ABI and SLE. Despite these limitations, our findings call attention to use ABI as a simple, noninvasive technique for the detection of accelerated atheroma in young patients with SLE.

CONCLUSION:

Mild abnormal ABI occurs with high frequency (16%) in Iraqi patients with SLE. Males, smoking

history, and cyclophosphamide therapy are significant predictors.

ACKNOWLEDGMENT:

The authors gratefully thank Dr. Nidhal M. Musa (DMRD), Dr.Naghham M. Utba (DMRD) , Dr. Thikra N. Hashim (DMRD), and Dr. Ali Hasson Jasim (DMRD) from the institute of radiology for their supporting the project.

REFERENCES:

1. Benedict R H B , Shucard J L , Zivadinov R, and Shucard D W. Neuropsychological Impairment in Systemic Lupus Erythematosus: A Comparison with Multiple Sclerosis. *Neuropsychol Rev* . 2008;18: 149–66. doi:10.1007/s11065-008-9061-2.
2. Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of SLE. *Am J Med* 1976; 60:221–25.
3. Greenland P, Abrams J, Aurigemma GP, et al. Prevention Conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. *Circulation* 2000;101:16 –22.
4. Esdaille JM, Abrahamowicz M, Grodzicky T et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. *Arthritis Rheum* 2001;44: 23-31
5. Hirsch AT, Haskal ZJ, Hertzner NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease. *Circulation* 2006;113: 463–54.
6. Greenland P, Abrams J, Aurigemma GP, et al. Prevention Conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. *Circulation* 2000;101:16 –22.
7. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982; 25:1271–77.
8. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997;40: 1725-26.

9. Gladman DD, Ibanez D, Urowitz MB. SLE disease activity index 2000. *J rheumatol* 2002; 29: 288-91.
10. Criqui MH, Denenberg JO, Langer RD, Fronck A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. *Vasc Med* 1997;2: 221-26.
11. Resnick HE, Lindsay RS, McDermott MM, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. *Circulation* 2004; 109: 733-39.
12. Theodoridou A, Beuto L, Cruz DP, et al. Prevalence and associations of abnormal ankle-brachial index in systemic lupus erythematosus: a pilot study. *Ann Rheum Dis* 2003;62;1199-203.
13. Ward MM. Premature morbidity from cardiovascular and cerebro-vascular disease in women with systemic lupus erythematosus. *Arthritis Rheum* 1999; 42: 338–46.
14. Shinozaki T, Hasegawa T, Yano E. Ankle-arm index as an indicator of atherosclerosis: its application as a screening method. *J Clin Epidemiol* 1998; 51:1263–69.
15. Tsai AW, Folsom AR, Rosamond WD, Jones DW. Ankle-brachial index and 7-year ischemic stroke incidence: the ARIC study. *Stroke* 2001; 32:1721–24.
16. Newman AB, Shemanski L, Manolio TA, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. *Arterioscler Thromb Vasc Biol* 1999; 19:538–45.
17. Abbott RD, Rodriguez BL, Petrovitch H, et al. Ankle-brachial blood pressure in elderly men and the risk of stroke: the Honolulu Heart Program. *J Clin Epidemiol* 2001;54:973–78.
18. Abbott RD, Petrovitch H, Rodriguez BL, et al. Ankle/brachial blood pressure in men .70 years of age and the risk of coronary heart disease. *Am J Cardiol* 2000; 86:280–84.
19. Lijmer JG, Hunink MG, van den Dungen JJ, et al. ROC analysis of noninvasive tests for peripheral arterial disease. *Ultrasound Med Biol* 1996;22:391–98.
20. Al-Kaabi JK, levison R, Pullar T, et al. Rheumatoid arthritis and macrovascular disease. *Rheumatology* 2003; 42: 292-97.
21. Christodoulou C, Zain M, Bertolaccini ML. Prevalence of abnormal ankle brachial index in patients with antiphospholipid syndrome with pregnancy loss but without thrombosis: a controlled study. *Ann Rheum Dis* 2006; 65: 683-84.
22. Satish MR, Patrick DK, Brian EB. Prevalence of abnormal ankle brachial index in patients with primary Sjogren's syndrome. *Clinic Rheum* 2009;28: 587-90.
23. Khudhir ZM. The Role of Plasma Lipoprotein and Carotid Doppler in Detecting Premature Atherosclerosis among Iraqi Patients with Systemic Lupus Erythematosus. *IPMJ* 2008;7:147-51.